Article Abstract:
High doses of danaparoid may be superior to unfractionated heparin in the treatment of venous thromboembolism. Venous thromboembolism occurs when blood clots form and block veins. Researchers compared the effectiveness of high and low doses of danaparoid with heparin infusions in 188 patients with thromboembolism. One group of 63 patients received a high dose of 2,000 units of danaparoid intravenously and by injection thereafter. Low dose danaparoid consisted of 1,250 units, while heparin infusions started at 2,500 units. Treatment continued for at least five days, or until anticoagulation was achieved. Only 13 percent of the patients in the high- dose danaparoid group had recurring thromboembolic symptoms compared to 28% in the heparin group. Bleeding was minimal among all three groups.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Factor V Arg506Gln mutation, a genetic blood clotting defect, may not be a risk factor for death from heart disease in older women. The mutation represents a risk of venous thrombosis for young women and for women smokers. Researchers found no evidence of mutation-linked mortality in 524 cardiovascular deaths when compared to 517 deaths from other causes. No effect was found for smoking, hypertension, or obesity.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Study findings show that socioeconomic status (SES) and aortic atherosclerosis are related in women, but relationships were not found in men. It seems SES affects rates of cardiovascular disease before clinical manifestation. Socioeconomic status and aortic atherosclerosis have been studied in elderly Dutch people using data from the Rotterdam Study, which collected data on 4,451 people 55-94 years of age.
User Contributions:
Comment about this article or add new information about this topic: